Content Type: Commentary & Opinion

The 21st Century Cures Act—Will It Take Us Back in Time? (Reply)

March 16, 2026

Regulation of Drugs for Early Alzheimer’s Disease

March 16, 2026

Recent Trends in Prescription Drug Launch Prices (Reply)

March 16, 2026

Physician Trainees’ Interactions with the Pharmaceutical Industry (Reply)

March 16, 2026

QALYs in Health Resource Usage Decisions (Reply)

March 16, 2026

The Supreme Court, Process Patents, and Medical Innovation

March 16, 2026

Antibiotic Development Incentives That Reflect Societal Value of Antibiotics (Reply)

March 16, 2026

The FDA Amendments Act of 2007—Assessing Its Effects a Decade Later

March 16, 2026

Is the Concept of Clinical Equipoise Still Relevant to Research?

March 16, 2026

Improving the Use of FDA Advisory Committees

March 16, 2026

Prioritization of Generic Drug Review (Reply)

March 16, 2026

Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility

March 16, 2026